Lisaftoclax

A Global Multicenter, Double-blind, Randomized, Registrational Phase 3 Study of Lisaftoclax (APG-2575) in Combination With Azacitidine (AZA) in Patients With Newly Diagnosed Higher Risk Myelodysplastic Syndrome (HR-MDS) (GLORA-4).

More Information

Trial Status
Not yet accepting
Trial Phase
Phase 3
Enrollment
464 patients (estimated)
Sponsors
Ascentage Pharma Group Inc.
Tags
BCL-2 Inhibitor, Placebo, Randomization
Trial Type
Treatment
Last Update
2 weeks ago
SparkCures ID
2010
NCT Identifier
NCT06641414

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print Report

Print a patient-friendly report to share with your patient.

(888) 803-1766

We can help answer any questions and connect you (or your patient) with the study team.

Schedule Call

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.